AveXis, Inc. (NASDAQ:AVXS) was the target of some unusual options trading on Thursday. Stock investors bought 1,046 call options on the stock. This represents an increase of 1,160% compared to the average volume of 83 call options.

AveXis (NASDAQ:AVXS) opened at $99.83 on Friday. AveXis has a 52-week low of $44.68 and a 52-week high of $108.27.

AveXis (NASDAQ:AVXS) last released its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same quarter in the prior year, the firm posted ($0.87) earnings per share. analysts forecast that AveXis will post -6.23 EPS for the current year.

In other AveXis news, VP Andrew F. Knudten sold 2,000 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $94.48, for a total transaction of $188,960.00. Following the sale, the vice president now directly owns 7,000 shares in the company, valued at approximately $661,360. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $97.25, for a total value of $173,105.00. Following the sale, the vice president now owns 1,780 shares in the company, valued at $173,105. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 52,340 shares of company stock worth $5,172,298. Company insiders own 18.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Morgan Stanley raised its holdings in AveXis by 8.4% during the first quarter. Morgan Stanley now owns 22,681 shares of the company’s stock valued at $1,724,000 after acquiring an additional 1,758 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in AveXis by 7.0% during the first quarter. Schwab Charles Investment Management Inc. now owns 54,865 shares of the company’s stock valued at $4,172,000 after acquiring an additional 3,579 shares during the period. Bank of Montreal Can raised its holdings in AveXis by 7,058.8% during the second quarter. Bank of Montreal Can now owns 30,425 shares of the company’s stock valued at $2,500,000 after acquiring an additional 30,000 shares during the period. Russell Investments Group Ltd. raised its holdings in AveXis by 41.7% during the second quarter. Russell Investments Group Ltd. now owns 24,871 shares of the company’s stock valued at $2,043,000 after acquiring an additional 7,321 shares during the period. Finally, Pictet Asset Management Ltd. raised its holdings in AveXis by 2.9% during the second quarter. Pictet Asset Management Ltd. now owns 158,062 shares of the company’s stock valued at $11,183,000 after acquiring an additional 4,456 shares during the period. Institutional investors own 92.88% of the company’s stock.

Several brokerages have commented on AVXS. Evercore ISI assumed coverage on AveXis in a research note on Wednesday, August 16th. They set an “outperform” rating and a $120.00 target price on the stock. Royal Bank Of Canada restated a “hold” rating and issued a $92.00 price target on shares of AveXis in a research note on Thursday, November 2nd. Wells Fargo & Company restated an “outperform” rating and issued a $134.00 price target (up from $89.00) on shares of AveXis in a research note on Tuesday, September 5th. BMO Capital Markets restated an “outperform” rating and issued a $123.00 price target on shares of AveXis in a research note on Saturday, September 30th. Finally, UBS restated a “buy” rating and issued a $122.00 price target (up from $95.00) on shares of AveXis in a research note on Tuesday, October 3rd. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating to the stock. AveXis presently has a consensus rating of “Buy” and an average price target of $110.67.

TRADEMARK VIOLATION WARNING: “Traders Purchase Large Volume of AveXis Call Options (AVXS)” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/10/traders-purchase-large-volume-of-avexis-call-options-avxs.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.